The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Ting‐Chao Chou, Paul Talalay · Advances in Enzyme Regulation · 1984 · 7.2K citations

Pharmacy, Pharmacokinetics, Pharmacology +16

The selectivity of protein kinase inhibitors: a further update

Jenny Bain, Lorna Plater, Matt Elliott et al. · Biochemical Journal · 2007 · 2.5K citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

Timothy R. Peterson, Mathieu Laplante, Carson C. Thoreen et al. · Cell · 2009 · 1.2K citations · Full text

Medicine, Cancer Biology, Oncology +14

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al. · Journal of Medicinal Chemistry · 2008 · 746 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Evaluation of Combination Chemotherapy

Liang Zhao, M. Guillaume Wientjes, Jessie L.‐S. Au · Clinical Cancer Research · 2004 · 377 citations

Medicine, Pharmacology, Pharmacotherapy +14